Pfizer Inc. (NYSE:PFE) Shares Sold by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S trimmed its position in Pfizer Inc. (NYSE:PFE - Free Report) by 9.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,002,256 shares of the biopharmaceutical company's stock after selling 110,627 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S's holdings in Pfizer were worth $26,590,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Nordea Investment Management AB lifted its position in Pfizer by 36.1% during the 4th quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock valued at $108,002,000 after acquiring an additional 1,080,822 shares during the period. Parsons Capital Management Inc. RI increased its holdings in Pfizer by 118.7% during the fourth quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock valued at $7,820,000 after buying an additional 159,984 shares during the last quarter. Copley Financial Group Inc. bought a new position in Pfizer in the 3rd quarter worth $577,000. Mcdonald Partners LLC increased its holdings in Pfizer by 9.9% in the 4th quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company's stock worth $2,926,000 after acquiring an additional 9,963 shares in the last quarter. Finally, Merit Financial Group LLC raised its position in shares of Pfizer by 60.8% during the 4th quarter. Merit Financial Group LLC now owns 127,967 shares of the biopharmaceutical company's stock valued at $3,395,000 after purchasing an additional 48,397 shares during the period. Institutional investors own 68.36% of the company's stock.

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the company's stock in a transaction dated Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 0.06% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on PFE shares. Cantor Fitzgerald started coverage on shares of Pfizer in a research note on Tuesday. They set a "neutral" rating and a $24.00 target price for the company. Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. The Goldman Sachs Group reissued a "neutral" rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, UBS Group dropped their price objective on Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a research note on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, Pfizer has an average rating of "Moderate Buy" and a consensus target price of $29.57.

Pfizer Price Performance

NYSE PFE traded down $0.12 during mid-day trading on Wednesday, hitting $22.41. The stock had a trading volume of 32,999,021 shares, compared to its average volume of 40,427,391. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm's 50 day moving average is $24.75 and its 200 day moving average is $26.08. The stock has a market capitalization of $127.10 billion, a price-to-earnings ratio of 15.89, a PEG ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same period last year, the firm posted $0.10 earnings per share. The company's revenue for the quarter was up 24.7% on a year-over-year basis. Equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.